Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 14, 2025

Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause

View original at nasdaq.com
Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause The S&P 500 Index ($SPX) (SPY) on Friday closed down -0.05%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.65%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.06%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The October jobs report will be released without the unemployment rate

    80% confidence
  • It would be hard to support another rate cut unless there is convincing evidence that inflation is coming down faster than expectations or more than gradual cooling in labor market

    80% confidence
  • Paramount, Comcast, and Netflix are preparing to bid for Warner Bros Discovery

    80% confidence
  • Recent pullback in DoorDash stock is a buying opportunity

    80% confidence
  • The six-week government closure reduced real GDP growth in the current quarter by 1.5 percentage points, with more than half potentially recovered early next year

    80% confidence
  • 82% of reporting S&P 500 companies exceeded forecasts, on course for best quarter since 2021, with Q3 earnings up 14.6% vs expectations of 7.2%

    80% confidence
  • Further cuts in interest rates won't do much to patch over any cracks in the labor market but could have longer-lasting effects on inflation as commitment to 2% objective increasingly comes into question

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com